James L. Gulley
#84,028
Most Influential Person Now
Cancer researcher
James L. Gulley's AcademicInfluence.com Rankings
James L. Gulleylaw Degrees
Law
#2447
World Rank
#3045
Historical Rank
Common Law
#99
World Rank
#108
Historical Rank
James L. Gulleybiology Degrees
Biology
#8186
World Rank
#11226
Historical Rank
Immunology
#480
World Rank
#496
Historical Rank
Download Badge
Law Biology
Why Is James L. Gulley Influential?
(Suggest an Edit or Addition)According to Wikipedia, James L. Gulley is an American cancer researcher and the Director of the Medical Oncology Service at National Cancer Institute. Early life and education He graduated from Loma Linda University, California and his M.D./Ph.D. Medical Scientist Training Program, at National Institutes of Health and his dissertation on tumor immunology. Later, Gulley did his residency in internal medicine at Emory University in 1998, followed by a medical oncology fellowship at the NCI.
James L. Gulley's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Papers
- Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group (2017) (1274)
- Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. (2010) (836)
- Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study (2017) (495)
- Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. (2018) (438)
- Androgen deprivation therapy for prostate cancer. (2005) (411)
- Combining a Recombinant Cancer Vaccine with Standard Definitive Radiotherapy in Patients with Localized Prostate Cancer (2005) (368)
- Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. (2004) (360)
- Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti–PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells (2015) (329)
- Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. (2012) (327)
- Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas. (2005) (301)
- A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. (2006) (289)
- Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer (2010) (284)
- Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial. (2017) (283)
- Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial (2019) (257)
- Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial. (2017) (241)
- Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors (2018) (234)
- Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV‐PSA) in patients with metastatic androgen‐independent prostate cancer (2002) (228)
- Pilot Study of Vaccination with Recombinant CEA-MUC-1-TRICOM Poxviral-Based Vaccines in Patients with Metastatic Carcinoma (2008) (220)
- Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer (2009) (214)
- Cancer Vaccines: Moving Beyond Current Paradigms (2007) (213)
- Current Landscape of Immunotherapy in Breast Cancer: A Review. (2019) (211)
- Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations (2018) (186)
- A Phase II Clinical Trial of Sorafenib in Androgen-Independent Prostate Cancer (2008) (175)
- A Pilot Study of CTLA-4 Blockade after Cancer Vaccine Failure in Patients with Advanced Malignancy (2007) (156)
- Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease (2018) (155)
- An update on androgen deprivation therapy for prostate cancer. (2010) (153)
- Immunotherapy of Prostate Cancer: Facts and Hopes (2017) (151)
- The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance (2019) (149)
- Enhanced Functionality of CD4+CD25highFoxP3+ Regulatory T Cells in the Peripheral Blood of Patients with Prostate Cancer (2008) (149)
- Higher Incidence of Osteonecrosis of the Jaw (ONJ) in Patients with Metastatic Castration Resistant Prostate Cancer Treated with Anti-Angiogenic Agents (2009) (147)
- Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors (2006) (146)
- Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. (2010) (140)
- Analysis of Overall Survival in Patients with Nonmetastatic Castration-Resistant Prostate Cancer Treated with Vaccine, Nilutamide, and Combination Therapy (2008) (140)
- Effects of conventional therapeutic interventions on the number and function of regulatory T cells (2013) (137)
- Avelumab (MSB0010718C; anti-PD-L1) in patients with recurrent/refractory ovarian cancer from the JAVELIN Solid Tumor phase Ib trial: Safety and clinical activity. (2016) (135)
- Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma: Phase 1b Results From the JAVELIN Solid Tumor Trial (2019) (134)
- Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances (2020) (133)
- Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer. (2007) (133)
- Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer (2019) (131)
- Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment (2017) (131)
- Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression. (2010) (129)
- A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer. (2001) (129)
- Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors (2019) (126)
- Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time. (2008) (126)
- Clinical safety of a viral vector based prostate cancer vaccine strategy. (2007) (125)
- Tumor Regression and Growth Rates Determined in Five Intramural NCI Prostate Cancer Trials: The Growth Rate Constant as an Indicator of Therapeutic Efficacy (2010) (122)
- A Pilot Study of MUC-1/CEA/TRICOM Poxviral-Based Vaccine in Patients with Metastatic Breast and Ovarian Cancer (2011) (122)
- Immunotherapy for Prostate Cancer: Recent Advances, Lessons Learned, and Areas for Further Research (2011) (116)
- A novel bifunctional anti-PD-L1/TGF-β Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells (2017) (114)
- Phase I Trial of a Yeast-Based Therapeutic Cancer Vaccine (GI-6301) Targeting the Transcription Factor Brachyury (2015) (113)
- Final analysis of a phase II trial using sorafenib for metastatic castration‐resistant prostate cancer (2009) (113)
- Immune Impact Induced by PROSTVAC (PSA-TRICOM), a Therapeutic Vaccine for Prostate Cancer (2013) (112)
- Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer. (2005) (110)
- Discovering clinical biomarkers of ionizing radiation exposure with serum proteomic analysis. (2006) (108)
- Synergizing radiation therapy and immunotherapy for curing incurable cancers. Opportunities and challenges. (2008) (108)
- A retrospective study of the time to clinical endpoints for advanced prostate cancer (2005) (108)
- If we build it they will come: targeting the immune response to breast cancer (2019) (107)
- Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive role. (2012) (106)
- Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy. (2011) (105)
- Sicca Syndrome Associated with Immune Checkpoint Inhibitor Therapy. (2019) (102)
- Safety and Immunologic Response of a Viral Vaccine to Prostate-Specific Antigen in Combination with Radiation Therapy when Metronomic-Dose Interleukin 2 Is Used as an Adjuvant (2008) (102)
- Impact of tumour volume on the potential efficacy of therapeutic vaccines. (2011) (101)
- A phase II study of perifosine in androgen independent prostate cancer (2005) (101)
- Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with previously treated, recurrent or refractory ovarian cancer: A phase Ib, open-label expansion trial. (2015) (98)
- Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial (2018) (96)
- White paper on microbial anti-cancer therapy and prevention (2018) (95)
- A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates (2014) (94)
- Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma (2014) (89)
- Identification and characterization of a human agonist cytotoxic T-lymphocyte epitope of human prostate-specific antigen. (2002) (87)
- The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells (2016) (86)
- Avelumab (MSB0010718C), an anti-PD-L1 antibody, in advanced NSCLC patients: A phase 1b, open-label expansion trial in patients progressing after platinum-based chemotherapy. (2015) (85)
- Clinical evaluation of TRICOM vector therapeutic cancer vaccines. (2012) (84)
- Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce (2020) (83)
- A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase III clinical trial using limited hormonal therapy. (2005) (79)
- Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma (2019) (78)
- Prospective Study Evaluating Na18F PET/CT in Predicting Clinical Outcomes and Survival in Advanced Prostate Cancer (2016) (78)
- Safety profile of avelumab in patients with advanced solid tumors: A pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials (2018) (77)
- PANVAC™-VF: poxviral-based vaccine therapy targeting CEA and MUC1 in carcinoma (2007) (76)
- Bethesda Handbook of Clinical Oncology (2000) (75)
- Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1 (2018) (74)
- First-in-Human Phase I Trial of a Tumor-Targeted Cytokine (NHS-IL12) in Subjects with Metastatic Solid Tumors (2018) (74)
- Enhancing efficacy of therapeutic vaccinations by combination with other modalities. (2007) (73)
- Anti–PD-L1 Treatment Induced Central Diabetes Insipidus (2017) (71)
- Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody (2017) (71)
- Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in second-line treatment of patients with non-small cell lung cancer: results from an expansion cohort of a phase 1 trial. (2020) (71)
- Docetaxel Alone or in Combination With a Therapeutic Cancer Vaccine (PANVAC) in Patients With Metastatic Breast Cancer: A Randomized Clinical Trial. (2015) (69)
- A randomized, phase II trial of ketoconazole plus alendronate versus ketoconazole alone in patients with androgen independent prostate cancer and bone metastases. (2005) (68)
- The Kinetics and Reproducibility of 18F-Sodium Fluoride for Oncology Using Current PET Camera Technology (2012) (67)
- Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced unresectable mesothelioma from the JAVELIN solid tumor phase Ib trial: Safety, clinical activity, and PD-L1 expression. (2016) (67)
- Combining radiation and immunotherapy for synergistic antitumor therapy. (2009) (62)
- Effect of TLR Agonists on the Differentiation and Function of Human Monocytic Myeloid-Derived Suppressor Cells (2015) (60)
- Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies (2020) (60)
- Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19 (2020) (60)
- Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors (2020) (60)
- A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancer (2008) (59)
- A Viral Vaccine Encoding Prostate-Specific Antigen Induces Antigen Spreading to a Common Set of Self-Proteins in Prostate Cancer Patients (2010) (58)
- Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trial (2019) (58)
- Radium-223 mechanism of action: implications for use in treatment combinations (2019) (58)
- Soluble CD27-Pool in Humans May Contribute to T Cell Activation and Tumor Immunity (2013) (55)
- Revised Overall Survival Analysis of a Phase II, Randomized, Double-Blind, Controlled Study of PROSTVAC in Men With Metastatic Castration-Resistant Prostate Cancer. (2017) (54)
- A Human Cytotoxic T-Lymphocyte Epitope and Its Agonist Epitope from the Nonvariable Number of Tandem Repeat Sequence of MUC-1 (2004) (53)
- Phase I open-label, multiple ascending dose trial of MSB0010718C, an anti-PD-L1 monoclonal antibody, in advanced solid malignancies. (2014) (53)
- Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccination (2011) (53)
- Phase I Study of Oral Lenalidomide in Patients With Refractory Metastatic Cancer (2009) (53)
- Nivolumab: promising survival signal coupled with limited toxicity raises expectations. (2014) (51)
- Preclinical and clinical studies of recombinant poxvirus vaccines for carcinoma therapy. (2007) (51)
- Prostate Cancer Immunotherapy (2011) (51)
- Therapeutic vaccines for prostate cancer. (2006) (50)
- Paradigm Shifts in Cancer Vaccine Therapy (2008) (50)
- Costimulatory molecules as adjuvants for immunotherapy. (2006) (49)
- TRICOM vector based cancer vaccines. (2006) (49)
- Phase I Study of a Poxviral TRICOM-Based Vaccine Directed Against the Transcription Factor Brachyury (2017) (48)
- A phase I study of TRC105 anti‐endoglin (CD105) antibody in metastatic castration‐resistant prostate cancer (2015) (48)
- Phase II clinical trial of cediranib in patients with metastatic castration‐resistant prostate cancer (2013) (47)
- Analyses of Recombinant Vaccinia and Fowlpox Vaccine Vectors Expressing Transgenes for Two Human Tumor Antigens and Three Human Costimulatory Molecules (2005) (47)
- Pre‐clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen‐independent prostate cancer (2007) (46)
- Safety, clinical activity, and PD-L1 expression of avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with metastatic urothelial carcinoma from the JAVELIN Solid Tumor phase Ib trial. (2016) (46)
- Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer (2019) (45)
- Serum Antibodies to Blood Group A Predict Survival on PROSTVAC-VF (2013) (45)
- Immuno-PET Imaging of the Programmed Cell Death-1 Ligand (PD-L1) Using a Zirconium-89 Labeled Therapeutic Antibody, Avelumab (2019) (44)
- Quick efficacy seeking trial (QuEST1): a novel combination immunotherapy study designed for rapid clinical signal assessment metastatic castration-resistant prostate cancer (2018) (44)
- Analyses of 123 Peripheral Human Immune Cell Subsets: Defining Differences with Age and between Healthy Donors and Cancer Patients Not Detected in Analysis of Standard Immune Cell Types (2016) (44)
- A national multicenter phase 2 study of prostate-specific antigen (PSA) pox virus vaccine with sequential androgen ablation therapy in patients with PSA progression: ECOG 9802. (2015) (44)
- Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers (2016) (43)
- Poxviral vectors for cancer immunotherapy (2012) (42)
- Increased Frequency of Venous Thromboembolism with the Combination of Docetaxel and Thalidomide in Patients with Metastatic Androgen‐Independent Prostate Cancer (2003) (42)
- Effect of cabozantinib on immunosuppressive subsets in metastatic urothelial carcinoma. (2014) (42)
- Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial. (2020) (42)
- Strategies for improving the management of immune-related adverse events (2020) (42)
- Humoral response to a viral glycan correlates with survival on PROSTVAC-VF (2014) (42)
- Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell carcinoma: phase Ib results from the JAVELIN Solid Tumor trial (2019) (41)
- A Phase II Clinical Trial of TRC105 (Anti‐Endoglin Antibody) in Adults With Advanced/Metastatic Urothelial Carcinoma (2017) (41)
- Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with metastatic or locally advanced solid tumors : assessment of safety and tolerability in a phase I, open-label expansion study (2015) (41)
- A Prospective Comparison of 18F-Sodium Fluoride PET/CT and PSMA-Targeted 18F-DCFBC PET/CT in Metastatic Prostate Cancer (2018) (41)
- A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation. (2009) (39)
- A randomized phase II study of docetaxel alone or in combination with PANVAC-V (vaccinia) and PANVAC-F (fowlpox) in patients with metastatic breast cancer (NCI 05-C-0229). (2006) (38)
- A Phase I Dose-Escalation Trial of BN-CV301, a Recombinant Poxviral Vaccine Targeting MUC1 and CEA with Costimulatory Molecules (2019) (38)
- Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis (2020) (37)
- Therapeutic vaccines in metastatic castration-resistant prostate cancer: principles in clinical trial design (2010) (37)
- ADCC employing an NK cell line (haNK) expressing the high affinity CD16 allele with avelumab, an anti‐PD‐L1 antibody (2017) (37)
- Product review: avelumab, an anti-PD-L1 antibody (2018) (37)
- Avelumab (MSB0010718C; anti-PD-L1) in patients with metastatic urothelial carcinoma from the JAVELIN solid tumor phase 1b trial: Analysis of safety, clinical activity, and PD-L1 expression. (2016) (37)
- Low Abundance of Circulating Tumor DNA in Localized Prostate Cancer (2019) (36)
- Phase I study of intraprostatic vaccine administration in men with locally recurrent or progressive prostate cancer (2013) (36)
- HEPCIDIN, ANAEMIA, AND PROSTATE CANCER (2011) (36)
- Neoadjuvant PROSTVAC prior to radical prostatectomy enhances T-cell infiltration into the tumor immune microenvironment in men with prostate cancer (2020) (36)
- The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma (2016) (36)
- Samarium-153-EDTMP (Quadramet®) with or without vaccine in metastatic castration-resistant prostate cancer: A randomized Phase 2 trial (2016) (36)
- A phase 2 study of olaparib and durvalumab in metastatic castrate-resistant prostate cancer (mCRPC) in an unselected population. (2018) (36)
- Endocrine-Related Adverse Events Related to Immune Checkpoint Inhibitors: Proposed Algorithms for Management. (2019) (36)
- Analyses of functions of an anti-PD-L1/TGFβR2 bispecific fusion protein (M7824) (2017) (35)
- Putting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel-T (2020) (35)
- Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia (2018) (35)
- Kinetics of serum androgen normalization and factors associated with testosterone reserve after limited androgen deprivation therapy for nonmetastatic prostate cancer. (2008) (34)
- Therapeutic vaccines (2013) (34)
- Endpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccines (2011) (33)
- Targeting the immune system in non-small-cell lung cancer: bridging the gap between promising concept and therapeutic reality. (2010) (33)
- A phase I study of oral CC-5013 (lenalidomide, Revlimid), a thalidomide derivative, in patients with refractory metastatic cancer. (2004) (33)
- New gene expressed in prostate: a potential target for T cell-mediated prostate cancer immunotherapy (2009) (33)
- The use of bisphosphonates in cancer patients (2007) (33)
- Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort (2020) (33)
- Combining vaccines and immune checkpoint inhibitors to prime, expand, and facilitate effective tumor immunotherapy (2018) (33)
- Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF- β and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial (2021) (33)
- A Phase I Trial Using a Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury)‐Based Immunotherapy Vaccine Regimen in Patients with Advanced Cancer (2019) (32)
- Promising novel immunotherapies and combinations for prostate cancer. (2009) (32)
- A phase II study of PROSTVAC-VF vaccine, and the role o f GM-CSF, in patients (pts) with metastatic androgen insensitive prostate cancer (AIPC) (2005) (31)
- A phase I clinical study of high dose ketoconazole plus weekly docetaxel for metastatic castration resistant prostate cancer. (2010) (31)
- Augmented Radiologist Workflow Improves Report Value and Saves Time: A Potential Model for Implementation of Artificial Intelligence. (2020) (31)
- Therapeutic cancer vaccines. (2014) (31)
- Up‐regulation of proliferative and migratory genes in regulatory T cells from patients with metastatic castration‐resistant prostate cancer (2013) (31)
- Perspectives on sipuleucel-T: Its role in the prostate cancer treatment paradigm (2015) (30)
- The role of soluble CD40L in immunosuppression (2013) (30)
- Overall survival (OS) analysis of a phase l trial of a vector-based vaccine (PSA-TRICOM) and ipilimumab (Ipi) in the treatment of metastatic castration-resistant prostate cancer (mCRPC). (2010) (29)
- HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study (2021) (29)
- TARP vaccination is associated with slowing in PSA velocity and decreasing tumor growth rates in patients with Stage D0 prostate cancer (2016) (28)
- Analyses of Pretherapy Peripheral Immunoscore and Response to Vaccine Therapy (2016) (28)
- A phase II trial of thalidomide, bevacizumab, and docetaxel in patients (pts) with metastatic androgen-independent prostate cancer (AIPC) (2007) (28)
- Nascent prostate cancer heterogeneity drives evolution and resistance to intense hormonal therapy (2020) (28)
- Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging (2021) (28)
- A phase II randomized clinical trial of samarium-153 EDTMP (Sm-153) with or without PSA-TRICOM vaccine in metastatic castration-resistant prostate cancer (mCRPC) after docetaxel. (2013) (27)
- Pan-Bcl-2 Inhibitor, GX15-070 (Obatoclax), Decreases Human T Regulatory Lymphocytes while Preserving Effector T Lymphocytes: A Rationale for Its Use in Combination Immunotherapy (2014) (27)
- Enhanced Functionality of CD 4 + CD 25 highFoxP 3 + RegulatoryTCells in the Peripheral Blood of Patients with Prostate Cancer (2008) (26)
- Myocarditis in a patient treated with Nivolumab and PROSTVAC: a case report (2018) (26)
- Chemotherapy for Prostate Cancer: Finally an Advance! (2004) (26)
- Avelumab in metastatic castration-resistant prostate cancer (mCRPC). (2017) (26)
- Bony metastatic disease responses to sorafenib (BAY 43-9006) independent of PSA in patients with metastatic androgen independent prostate cancer. (2006) (25)
- Sipuleucel-T: harbinger of a new age of therapeutics for prostate cancer (2011) (25)
- The generation and analyses of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic (2015) (25)
- Combining immunotherapies for the treatment of prostate cancer. (2017) (25)
- Vaccines as an Integral Component of Cancer Immunotherapy. (2018) (25)
- Immunotherapy biomarkers 2016: overcoming the barriers (2017) (24)
- Combining Vaccines with Conventional Therapies for Cancer. (2007) (24)
- Identification and characterization of agonist epitopes of the MUC1-C oncoprotein (2014) (24)
- Randomized phase II trial of docetaxel with or without PSA-TRICOM vaccine in patients with castrate-resistant metastatic prostate cancer: A trial of the ECOG-ACRIN cancer research group (E1809) (2015) (24)
- Safety and clinical activity of PD-L1 blockade in patients with aggressive recurrent respiratory papillomatosis (2019) (24)
- Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients with advanced non-small cell lung cancer. (2014) (24)
- A randomized phase II study of flutamide with or without PSA-TRICOM in nonmetastatic castration-resistant prostate cancer (CRPC). (2011) (24)
- Combination of vaccine and immune checkpoint inhibitor is safe with encouraging clinical activity (2012) (23)
- Pulmonary Toxicity During Prostate Cancer Treatment With Docetaxel and Thalidomide (2003) (23)
- Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cells (2020) (23)
- Demystifying Immunotherapy in Prostate Cancer: Understanding Current and Future Treatment Strategies (2013) (22)
- Treatment options for androgen-independent prostate cancer. (2003) (22)
- Therapeutic vaccines as a promising treatment modality against prostate cancer: rationale and recent advances (2014) (22)
- Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration‐resistant prostate cancer (2016) (22)
- A pilot safety trial investigating a vector-based vaccine targeting carcinoembryonic antigen in combination with radiotherapy in patients with gastrointestinal malignancies metastatic to the liver (2011) (21)
- Dual inhibition of TGF‐β and PD‐L1: a novel approach to cancer treatment (2021) (21)
- From clinical trials to clinical practice: therapeutic cancer vaccines for the treatment of prostate cancer (2011) (21)
- Pharmacokinetic profile and receptor occupancy of avelumab (MSB0010718C), an anti-PD-L1 monoclonal antibody, in a phase I, open-label, dose escalation trial in patients with advanced solid tumors. (2015) (21)
- OA18.03 Safety and Clinical Activity of Avelumab (MSB0010718C; Anti-PD-L1) in Patients with Advanced Thymic Epithelial Tumors (TETs) (2017) (21)
- Endocrine-Related Adverse Events Related to Immune Checkpoint Inhibitors: Proposed Algorithms for Management. (2020) (20)
- Phase I trial of BMS-986253, an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors. (2018) (20)
- Maturation of human dendritic cells with Saccharomyces cerevisiae (yeast) reduces the number and function of regulatory T cells and enhances the ratio of antigen-specific effectors to regulatory T cells. (2011) (20)
- Phase II study of satraplatin and prednisone in patients with metastatic castration-resistant prostate cancer: a pharmacogenetic assessment of outcome and toxicity. (2013) (20)
- Identification of cytotoxic T‐lymphocyte epitope(s) and its agonist epitope(s) of a novel target for vaccine therapy (PAGE4) (2007) (20)
- PSA-based vaccines for the treatment of prostate cancer (2006) (20)
- Future directions in tumor immunotherapy: CTLA4 blockade (2007) (19)
- Safety and activity of M7824, a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with HPV associated cancers. (2018) (19)
- A case report of multiple primary prostate tumors with differential drug sensitivity (2020) (19)
- Considerations for the combination of anticancer vaccines and immune checkpoint inhibitors (2016) (18)
- A phase II study of the anti-programmed death ligand-1 antibody durvalumab (D; MEDI4736) in combination with PARP inhibitor, olaparib (O), in metastatic castration-resistant prostate cancer (mCRPC). (2017) (18)
- Cognitive testing of tobacco use items for administration to patients with cancer and cancer survivors in clinical research (2016) (18)
- Phase II trial of thalidomide (T), bevacizumab (Bv), and docetaxel (Doc) in patients (pts) with metastatic castration-refractory prostate cancer (mCRPC) (2008) (18)
- Randomized, Double‐Blind, Placebo‐Controlled Phase II Study of Yeast‐Brachyury Vaccine (GI‐6301) in Combination with Standard‐of‐Care Radiotherapy in Locally Advanced, Unresectable Chordoma (2021) (17)
- Persistent hypocalcemia induced by zoledronic acid in a patient with androgen-independent prostate cancer and extensive bone metastases. (2007) (17)
- ABO blood type correlates with survival on prostate cancer vaccine therapy (2015) (17)
- Exploiting Synergy: Immune-Based Combinations in the Treatment of Prostate Cancer (2014) (17)
- Therapeutic vaccines for prostate cancer: a review of clinical data. (2005) (17)
- IgG Responses to Tissue-Associated Antigens as Biomarkers of Immunological Treatment Efficacy (2010) (16)
- Deep androgen receptor suppression in prostate cancer exploits sexually dimorphic renal expression for systemic glucocorticoid exposure. (2020) (16)
- Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC) (2021) (16)
- Use of pembrolizumab with or without pomalidomide in HIV-associated non-Hodgkin’s lymphoma (2021) (16)
- Immunotherapy and therapeutic vaccines in prostate cancer: an update on current strategies and clinical implications (2014) (16)
- Phase I Trial of a Modified Vaccinia Ankara Priming Vaccine Followed by a Fowlpox Virus Boosting Vaccine Modified to Express Brachyury and Costimulatory Molecules in Advanced Solid Tumors. (2019) (16)
- Overall survival (OS) analysis of a phase II study using a pox viral-based vaccine, PSA-TRICOM, in the treatment of metastatic, castrate-resistant prostate cancer (mCRPC): Implications for clinical trial design (2008) (15)
- Preliminary results from a phase 1 trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in advanced solid tumors. (2017) (15)
- Efficacy and safety of first-line avelumab in patients with advanced non-small cell lung cancer: results from a phase Ib cohort of the JAVELIN Solid Tumor study (2020) (15)
- Phase II trial of cediranib (AZD2171) in docetaxel-resistant, castrate-resistant prostate cancer (CRPC) (2008) (15)
- Prospect: A randomized double-blind phase 3 efficacy study of PROSTVAC-VF immunotherapy in men with asymptomatic/minimally symptomatic metastatic castration-resistant prostate cancer. (2015) (15)
- Novel clinical trials in androgen-independent prostate cancer. (2002) (15)
- A Randomized, Double-blind, Phase II Trial of PSA-TRICOM (PROSTVAC) in Patients with Localized Prostate Cancer: The Immunotherapy to Prevent Progression on Active Surveillance Study. (2018) (15)
- Combination of PDL-1 and PARP inhibition in an unselected population with metastatic castrate-resistant prostate cancer (mCRPC). (2017) (15)
- Perspectives on the clinical development of immunotherapy in prostate cancer (2018) (14)
- A phase I study of TRC105 (anti-CD105 [endoglin] antibody) in metastatic castration-resistant prostate cancer (mCRPC). (2011) (14)
- Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. (2012) (14)
- Combining active immunotherapy and immune checkpoint inhibitors in prostate cancer. (2015) (14)
- Interim analysis of a phase II randomized clinical trial of samrium-153 (Sm-153) with or without PSA-TRICOM vaccine in metastatic castration-resistant prostate cancer after docetaxel. (2012) (14)
- Novel approaches to treating the asymptomatic hormone-refractory prostate cancer patient. (2003) (14)
- The current and emerging role of immunotherapy in prostate cancer. (2010) (14)
- From clinical trials to clinical practice (1993) (13)
- Use of Magnetic Resonance Imaging to Identify Immune Checkpoint Inhibitor–Induced Inflammatory Arthritis (2020) (13)
- Exposure-response and PD-L1 expression analysis of second-line avelumab in patients with advanced NSCLC: Data from the JAVELIN Solid Tumor trial. (2017) (13)
- Docetaxel-based regimens, the standard of care for metastatic androgen-insensitive prostate cancer. (2005) (13)
- Safety and clinical activity of anti-programmed death-ligand 1 (PD-L1) antibody (ab) avelumab (MSB0010718C) in advanced thymic epithelial tumors (TETs). (2016) (13)
- Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced cancer: Safety data from 1300 patients enrolled in the phase 1b JAVELIN Solid Tumor trial. (2016) (13)
- 3090 Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with metastatic or recurrent non-small-cell lung cancer progressing after platinum-based chemotherapy: A phase Ib trial (2015) (13)
- Deep Small Bowel Segmentation with Cylindrical Topological Constraints (2020) (13)
- Results of PROSPECT: A randomized phase 3 trial of PROSTVAC-V/F (PRO) in men with asymptomatic or minimally symptomatic metastatic, castration-resistant prostate cancer. (2018) (13)
- Abstract CT075: Phase I evaluation of M7824, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus (HPV)-associated malignancies (2019) (13)
- A comparison of prostate cancer bone metastases on 18F-Sodium Fluoride and Prostate Specific Membrane Antigen (18F-PSMA) PET/CT: Discordant uptake in the same lesion (2018) (13)
- Therapeutic cancer vaccine fulfills the promise of immunotherapy in prostate cancer. (2011) (13)
- Results from a second-line (2L) NSCLC cohort treated with M7824 (MSB0011359C), a bifunctional fusion protein targeting TGF-β and PD-L1. (2018) (12)
- Poxviral-based vaccine elicits immunologic responses in prostate cancer patients (2014) (12)
- Developing immunotherapy strategies in the treatment of prostate cancer (2016) (12)
- 2749 Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with recurrent or refractory ovarian cancer: A phase Ib trial reporting safety and clinical activity (2015) (12)
- Phase II evaluation of the triple combination of PDS0101, M9241, and bintrafusp alfa in patients with HPV 16 positive malignancies. (2021) (12)
- Diffuse lichen planus-like keratoses and clinical pseudo-progression associated with avelumab treatment for Merkel cell carcinoma, a case report (2019) (12)
- M7824: A promising new strategy to combat cancer immune evasion (2018) (12)
- Novel Therapeutic Strategies in Prostate Cancer (2004) (12)
- A randomized pilot study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen independent prostate cancer. (2006) (12)
- 825: Follow-up Analysis of A Randomized Phase II Study of Docetaxel (D) and Thalidomide (T) in Androgen-Independent Prostate Cancer (AIPC): Updated Survival Data and Stratification by CYP2C19 Mutation Status (2005) (12)
- Finding an Immunologic Beachhead in the Prostate Cancer Microenvironment. (2018) (12)
- Therapeutic vaccines and immunotherapy in castration-resistant prostate cancer: current progress and clinical applications. (2013) (11)
- Resources Required for Semi-Automatic Volumetric Measurements in Metastatic Chordoma: Is Potentially Improved Tumor Burden Assessment Worth the Time Burden? (2016) (11)
- M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with heavily pretreated CRC: Preliminary results from a phase I trial. (2018) (11)
- National Cancer Institute intramural approach to advanced prostate cancer. (2002) (11)
- 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two (2016) (11)
- Predicting clinical outcomes in chordoma patients receiving immunotherapy: a comparison between volumetric segmentation and RECIST (2016) (11)
- Ferumoxytol-Enhanced MR Lymphography for Detection of Metastatic Lymph Nodes in Genitourinary Malignancies: A Prospective Study. (2020) (11)
- Editorial: Local Immunotherapy: A Way to Convert Tumors From "Cold" to "Hot". (2017) (11)
- Phase 1 open-label trial of intravenous administration of MVA-BN-brachyury-TRICOM vaccine in patients with advanced cancer (2021) (11)
- Checkpoint and PARP inhibitors, for whom and when (2017) (10)
- Strategies for optimizing the clinical impact of immunotherapeutic agents such as sipuleucel-T in prostate cancer. (2012) (10)
- 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one (2016) (10)
- Ipilimumab in prostate cancer (2013) (10)
- Phase II trial of bevacizumab (A), lenalidomide (R), docetaxel (D), and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). (2011) (10)
- First-in-human phase I trial of NHS-IL12 in advanced solid tumors. (2012) (10)
- Vaccines as Monotherapy and in Combination Therapy for Prostate Cancer (2010) (10)
- 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one (2016) (10)
- Sequential Prostate Magnetic Resonance Imaging in Newly Diagnosed High-risk Prostate Cancer Treated with Neoadjuvant Enzalutamide is Predictive of Therapeutic Response (2020) (10)
- Circulating Tumor Cell Subtypes and T-cell Populations as Prognostic Biomarkers to Combination Immunotherapy in Patients with Metastatic Genitourinary Cancer (2020) (10)
- Tumor in the Crossfire: Inhibiting TGF-β to Enhance Cancer Immunotherapy (2022) (10)
- Early changes in immune cell subsets with corticosteroids in patients with solid tumors: implications for COVID-19 management (2020) (10)
- Phase I trial of an enhanced prostate-specific antigen-based vaccine and anti-CTLA-4 antibody in patients with metastatic androgen-independent prostate cancer. (2007) (10)
- A Case Report of Sequential Use of a Yeast-CEA Therapeutic Cancer Vaccine and Anti-PD-L1 Inhibitor in Metastatic Medullary Thyroid Cancer (2020) (9)
- Improving the Odds in Advanced Breast Cancer With Combination Immunotherapy: Stepwise Addition of Vaccine, Immune Checkpoint Inhibitor, Chemotherapy, and HDAC Inhibitor in Advanced Stage Breast Cancer (2021) (9)
- Immunotherapy for prostate cancer: what's the future? (2006) (9)
- Phase 2 Study of Seviteronel (INO-464) in Patients With Metastatic Castration-Resistant Prostate Cancer After Enzalutamide Treatment. (2020) (9)
- Phase II trial of bevacizumab and lenalidomide with docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC). (2012) (9)
- Selection of the recommended phase 2 dose (RP2D) for M7824 (MSB0011359C), a bifunctional fusion protein targeting TGF-β and PD-L1. (2018) (9)
- A phase I study of TRC 105 anti-endoglin ( CD 105 ) antibody in metastatic castration-resistant prostate cancer (2015) (9)
- A phase II study of cabozantinib (XL184) in patients with advanced/metastatic urothelial carcinoma. (2013) (9)
- Effect of talactoferrin alfa on the immune system in adults with non-small cell lung cancer. (2013) (9)
- Strategies for the development of PSA-based vaccines for the treatment of advanced prostate cancer (2003) (9)
- Comparison of tumor assessments using RECIST 1.1 and irRECIST, and association with overall survival (2022) (9)
- Docetaxel and thalidomide as a treatment option for androgen- independent, nonmetastatic prostate cancer. (2003) (9)
- Phase I study of lenalidomide, a novel thalidomide analog, in patients with refractory metastatic cancer. (2006) (9)
- A randomized, prospective, phase II study to determine the efficacy of BCG given in combination with panvac versus BCG alone in adults with high grade non-muscle invasive bladder cancer who failed at least one induction course of BCG. (2014) (9)
- Preclinical and correlative studies of cabozantinib (XL184) in urothelial cancer (UC). (2013) (8)
- Immunologic Monitoring of Cellular Immune Responses in Cancer Vaccine Therapy (2011) (8)
- Final results from a phase I trial and expansion cohorts of cabozantinib and nivolumab (CaboNivo) alone or with ipilimumab (CaboNivoIpi) for metastatic genitourinary tumors. (2021) (8)
- Routine interval computed tomography to detect new soft‐tissue disease might be unnecessary in patients with androgen‐independent prostate cancer and metastasis only to bone (2007) (8)
- Prostate cancer immunotherapy: the path forward (2017) (8)
- Dual antiangiogenic therapy using lenalidomide and bevacizumab with docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC). (2012) (8)
- Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced adrenocortical carcinoma from the JAVELIN solid tumor phase Ib trial: Safety and clinical activity. (2016) (8)
- Enhanced neoepitope-specific immunity following neoadjuvant PD-L1 and TGF-β blockade in HPV-unrelated head and neck cancer (2022) (8)
- The generation and analysis of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic (2015) (8)
- Avelumab for the treatment of metastatic Merkel cell carcinoma. (2017) (8)
- Dual PD-L1 and TGF-b blockade in patients with recurrent respiratory papillomatosis (2021) (8)
- Successful 5-fluorouracil (5-FU) infusion re-challenge in a metastatic colorectal cancer patient with coronary artery disease who experienced symptoms consistent with coronary vasospasm during first 5-FU infusion. (2019) (8)
- NCI experience using yeast-brachyury vaccine (GI-6301) in patients (pts) with advanced chordoma. (2014) (8)
- A phase II study of cabozantinib in patients (pts) with relapsed or refractory metastatic urothelial carcinoma (mUC). (2014) (8)
- 957O Long-term follow-up of patients (pts) with human papillomavirus (HPV)–associated malignancies treated with bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1 (2021) (8)
- Avelumab (anti–PD-L1) in patients with platinum-treated advanced NSCLC: 2.5-year follow-up from the JAVELIN Solid Tumor trial. (2018) (8)
- A Comparison of 18F-DCFPyL, 18F-NaF, and 18F-FDG PET/CT in a Prospective Cohort of Men with Metastatic Prostate Cancer (2021) (7)
- Safety profile of avelumab in patients with advanced solid tumors: A JAVELIN pooled analysis of phase 1 and 2 data. (2017) (7)
- Vaccines for the Treatment of Cancer (2004) (7)
- A Randomized Phase II Trial of mFOLFOX6 + Bevacizumab Alone or with AdCEA Vaccine + Avelumab Immunotherapy for Untreated Metastatic Colorectal Cancer. (2022) (7)
- Treatment of Castration-Resistant Prostate Cancer: Updates on Therapeutics Targeting the Androgen Receptor Signaling Pathway (2010) (7)
- Efficacy and immune-related adverse event associations in avelumab-treated patients (2020) (7)
- Updated results of M7824 (MSB0011359C): A bifunctional fusion protein targeting TGF-β and PD-L1, in second-line (2L) NSCLC. (2018) (7)
- A randomized, double-blind, phase II clinical trial of GI-6301 (yeast-brachyury vaccine) versus placebo in combination with standard of care definitive radiotherapy in locally advanced, unresectable, chordoma. (2020) (7)
- Cancer vaccines: current directions and perspectives in prostate cancer. (2009) (7)
- Randomized phase III trial of thalidomide (Th) or placebo (P) for non-metastatic PSA recurrent prostate cancer (PCa) treated with intermittent therapy (2008) (7)
- Therapeutic prostate cancer vaccines: a review of the latest developments. (2008) (7)
- The evolving role of immunotherapy in prostate cancer (2016) (7)
- Immunological and genomic correlates of response to anti-PD1 checkpoint therapy in mismatch proficient and deficient patients with metastasized castration resistant prostate cancer. (2018) (7)
- A novel ELISPOT assay to enhance detection of antigen-specific T cells employing antigen-presenting cells expressing vector-driven human B7-1. (2003) (6)
- A phase I study of a yeast-based therapeutic cancer vaccine, GI-6301, targeting brachyury in patients with metastatic carcinoma. (2014) (6)
- Identification and validation of expressed HLA-binding breast cancer neoepitopes for potential use in individualized cancer therapy (2021) (6)
- Avelumab in patients with previously treated mesothelioma: Updated phase 1b results from the JAVELIN Solid Tumor trial. (2018) (6)
- A randomized phase 2 study of bicalutamide with or without metformin for biochemical recurrence in overweight or obese prostate cancer patients (BIMET-1) (2022) (6)
- Prospects for the future of prostate cancer vaccines (2016) (6)
- Abstract P5-16-06: A phase 2 randomized trial of docetaxel (DOC) alone or in combination with therapeutic cancer vaccine, CEA-, MUC-1-TRICOM (PANVAC) (2012) (6)
- Cabozantinib plus docetaxel and prednisone in metastatic castration‐resistant prostate cancer (2020) (6)
- Appropriate Use Criteria for Imaging Evaluation of Biochemical Recurrence of Prostate Cancer After Definitive Primary Treatment (2020) (6)
- Five-year overall survival (OS) in non-metastatic androgen-independent prostate cancer (AIPC) patients (pts) treated with nilutamide (N), vaccine (V), and combination therapy (2007) (6)
- Predicting cancer immunotherapy response from gut microbiomes using machine learning models (2022) (6)
- Clinical and immunologic impact of short course enzalutamide without androgen deprivation therapy for biochemically recurrent prostate cancer. (2016) (6)
- Immune correlates of clinical parameters in patients with HPV-associated malignancies treated with bintrafusp alfa (2022) (6)
- Evaluation of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in cervical cancer: Data from phase 1 and phase 2 studies. (2021) (6)
- Detection and Characterization of Circulating Tumour Cells from Frozen Peripheral Blood Mononuclear Cells (2015) (6)
- 3110 Safety and clinical activity of avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with advanced, unresectable mesothelioma: A phase IB trial (2015) (6)
- IMMUNOLOGIC RESPONSE TO A THERAPEUTIC CANCER VACCINE (PANVAC): INITIAL RESULTS FROM A RANDOMIZED PHASE 2 CLINICAL TRIAL: MP15‐10 (2017) (6)
- Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer (2021) (6)
- Clodronate in the prevention and treatment of skeletal metastasis (2005) (6)
- Phase I Neoadjuvant Study of Intravesical Recombinant Fowlpox-GM-CSF (rF-GMCSF) or Fowlpox-TRICOM (rF-TRICOM) in Patients with Bladder Carcinoma (2019) (5)
- Cediranib (AZD2171) in docetaxel-resistant, castration-resistant prostate cancer (CRPC). (2009) (5)
- A phase II trial of docetaxel (D), estramustine (E) and thalidomide (T) in patients with metastatic androgen-independent prostate cancer (AIPC) (2005) (5)
- Two-year follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, for second-line (2L) treatment of non-small cell lung cancer (NSCLC). (2020) (5)
- Immunotherapy for biochemically recurrent prostate cancer. (2018) (5)
- Identification by digital immunohistochemistry of intratumoral changes of immune infiltrates after vaccine in the absence of modifications of PBMC immune cell subsets (2014) (5)
- Avelumab treatment for metastatic urothelial carcinoma in the phase Ib JAVELIN Solid Tumor Study: Updated safety and efficacy analysis with ≥ two years of follow-up. (2019) (5)
- PANVAC vaccine alone or with docetaxel for patients with metastatic breast cancer (2008) (5)
- PSA progression compared to radiographic or clinical progression in metastatic castration-resistant prostate cancer patients treated with enzalutamide. (2020) (5)
- Strengthening Agricultural Research in Africa (1999) (5)
- Phase 1b study of avelumab in advanced previously treated mesothelioma: long-term follow-up from JAVELIN Solid Tumor. (2018) (5)
- Phase I, dose-escalation, clinical trial of MVA-Brachyury-TRICOM vaccine demonstrating safety and brachyury-specific T cell responses (2015) (5)
- Acquired Coagulopathy With Immune Checkpoint Inhibitors: An Underrecognized Association Between Inflammation and Coagulation (2020) (5)
- The Potential Role for Immunotherapy in Biochemically Recurrent Prostate Cancer. (2020) (5)
- Prostate cancer: Better VISTAs ahead? Potential and pitfalls of immunotherapy (2017) (5)
- A pilot trial of a carcinoembryonic antigen/ TRICOM-based vaccine and radiation to liver metastases in patients with carcinoembryonic antigen-positive solid tumors. (2006) (5)
- A Phase 2 Randomized Trial of Docetaxel Alone or in Combination with Therapeutic Cancer Vaccine, CEA-, MUC-1-Tricom (2012) (5)
- Prolonged response to nilutamide in a patient with stage D0.5 prostate cancer who previously failed androgen deprivation therapy. (2005) (5)
- PSA (2020) (5)
- Osteonecrosis of the jaw (ONJ) in androgen-independent prostate cancer (AIPC) patients receiving ATTP (bevacizumab, docetaxel, thalidomide, and prednisone) (2007) (5)
- Deep Learning Based Staging of Bone Lesions From Computed Tomography Scans (2021) (5)
- Updated analysis of a phase II study using sorafenib (S) for metastatic castrate-resistant prostate cancer (mCRPC) (2008) (4)
- Safety and preliminary clinical activity of JNJ-63898081 (JNJ-081), a PSMA and CD3 bispecific antibody, for the treatment of metastatic castrate-resistant prostate cancer (mCRPC). (2022) (4)
- Significant prostate-specific antigen (PSA) response to low-dose ketoconazole in a patient with non-metastatic androgen-independent prostate cancer (AIPC) and a review of the literature. (2007) (4)
- mpMRI preoperative staging in men treated with antiandrogen and androgen deprivation therapy before robotic prostatectomy. (2019) (4)
- A phase II study of a yeast-based therapeutic cancer vaccine, GI-6207, targeting CEA in patients with minimally symptomatic, metastatic medullary thyroid cancer. (2013) (4)
- A retrospective analysis of intramural NCI prostate cancer trials: Progress made and insights gleaned. (2010) (4)
- 2630 Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with locally advanced or metastatic urothelial carcinoma: A phase Ib trial (2015) (4)
- (R)Evolutionary therapy: the potential of immunotherapy to fulfill the promise of personalized cancer treatment. (2014) (4)
- 616MO Efficacy of BN-brachyury (BNVax) + bintrafusp alfa (BA) + N-803 in castration-resistant prostate cancer (CRPC): Results from a preliminary analysis of the Quick Efficacy Seeking Trial (QuEST1) (2020) (4)
- Therapeutic vaccines for prostate cancer: what have we learned? (2008) (4)
- Progress in prostate cancer imaging. (2012) (4)
- Highlights of the 31st annual meeting of the Society for Immunotherapy of Cancer (SITC), 2016 (2017) (4)
- Interrogation of the cellular immunome of cancer patients with regard to the COVID-19 pandemic (2021) (4)
- A phase II study of BAY 43–9006 in patients with androgen-independent prostate cancer (AIPC) with proteomic profiling (2005) (4)
- A pilot trial of neoantigen DNA vaccine in combination with nivolumab/ipilimumab and prostvac in metastatic hormone-sensitive prostate cancer (mHSPC). (2021) (4)
- A phase II trial of docetaxel, thalidomide, bevacizumab, and prednisone in patients (pts) with metastatic androgen-independent prostate cancer (AIPC). (2006) (4)
- A comparison of 18 F-DCFPyL, 18 F-NaF and 18 F-FDG PET/CT in a prospective cohort of men with metastatic prostate cancer (2021) (4)
- A phase I trial of a yeast-based therapeutic cancer vaccine targeting CEA. (2011) (4)
- Recent advances in the use of therapeutic cancer vaccines in genitourinary malignancies (2014) (4)
- Abstract 4901: Short-course enzalutamide reveals immune activating properties in patients with biochemically recurrent prostate cancer (2016) (4)
- Immunotherapy: Shifting the Balance of Cell-Mediated Immunity and Suppression in Human Prostate Cancer (2012) (4)
- Immunotherapy in genitourinary malignancies (2016) (3)
- The emerging role of bisphosphonates in prostate cancer. (2004) (3)
- 8PDPhase I JAVELIN solid tumor trial of avelumab (MSB0010718C), an anti-PD-L1 antibody: Safety and pharmacokinetics (2015) (3)
- Dramatic and prolonged PSA response after retreatment with a PSA vaccine. (2013) (3)
- Antibody-dependent cellular cytotoxicity ( ADCC ) activity of a novel anti-PD-L 1 antibody avelumab ( MSB 0010718 C ) on human tumor cells (2015) (3)
- Phase Ib, open-label, dose-escalation study of M9241 (NHS-IL12) plus avelumab in patients (pts) with advanced solid tumours (2019) (3)
- Treating systemic prostate cancer: emerging drug targets and therapies (2000) (3)
- Avelumab in patients with previously treated metastatic melanoma: Phase 1b results from the JAVELIN Solid Tumor trial. (2018) (3)
- A Case of Anti-PD-L1-associated Remitting Seronegative Symmetric Synovitis With Pitting Edema. (2019) (3)
- Toward an off-the-shelf vaccine for B-cell malignancies. (2012) (3)
- Avelumab demonstrates promise in advanced NSCLC (2017) (3)
- Infusion-related reactions with administration of avelumab: mild and manageable side effects. (2017) (3)
- Morphological changes induced by intraprostatic PSA-based vaccine in prostate cancer biopsies (phase I clinical trial). (2018) (3)
- Avelumab: is it time to get excited? (2018) (3)
- Routine interval computed tomography in detecting new soft tissue disease in patients with androgen-independent prostate cancer (AIPC) and only bone metastasis. (2006) (3)
- Moving the goal posts in prostate cancer trials. (2015) (3)
- A phase I feasibility study of an intraprostatic prostate-specific antigen-based vaccine in patients with prostate cancer with local failure after radiation therapy or clinical progression on androgen-deprivation therapy in the absence of local definitive therapy. (2006) (3)
- A phase II study of trebananib (AMG 386) and abiraterone in metastatic castration resistant prostate cancer. (2014) (3)
- Bethesda Handbook of Clinical Oncology, Second Edition, for PDA: Powered by Skyscape, Inc. (2005) (3)
- MP16-14 CLINICAL OUTCOMES OF A RANDOMIZED, PROSPECTIVE, PHASE II STUDY TO DETERMINE THE EFFICACY OF BACILLUS CALMETTE-GUERIN (BCG) GIVEN IN COMBINATION WITH PANVAC VERSUS BCG GIVEN ALONE IN ADULTS WITH HIGH GRADE BCG-REFRACTORY NON-MUSCLE INVASIVE BLADDER CANCER (2021) (3)
- THERAPEUTIC VACCINES for CANCER (2013) (3)
- Neoadjuvant Immunotherapy: An Evolving Paradigm Shift? (2021) (3)
- MPAPASS software enables stitched multiplex, multidimensional EV repertoire analysis and a standard framework for reporting bead-based assays (2022) (3)
- 879TiP Phase II study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in platinum-experienced advanced cervical cancer (2020) (3)
- Cabozantinib (C) plus docetaxel (D) and prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC). (2015) (3)
- Identification of tumor associated immune responses against brachyury, a transcription factor and driver of EMT, in chordoma patients receiving a yeast-brachyury vaccine (gi-6301) (2014) (3)
- Safety profile of recombinant poxviral TRICOM vaccines. (2013) (3)
- 7002 Further analysis of a Phase II randomized controlled trial (RCT) of a poxviral-based PSA targeted immunotherapy in metastatic castration-resistant prostate cancer (mCRPC) (2009) (3)
- Early treatment gets the benefit. (2006) (2)
- The Use of T Cell Costimulation to Enhance the Immunogenicity of Tumors (2014) (2)
- Initial PSA oscillations precede prolonged stable disease in a patient treated with a therapeutic cancer vaccine. (2012) (2)
- Efficacy of abiraterone and enzalutamide in patients who had disease progression within twelve months of completing docetaxel for metastatic castration sensitive prostate cancer. (2019) (2)
- Cure of syngeneic carcinomas with targeted IL-12 through obligate reprogramming of lymphoid and myeloid immunity (2022) (2)
- Effect of rilimogene galvacirepvec/rilimogene glafolivec on intra/peritumoral immune infiltrate in patients with localized prostate cancer undergoing radical prostatectomy. (2018) (2)
- A phase I study of TRC105 (anti-CD105 monoclonal antibody) in metastatic castration-resistant prostate cancer (mCRPC). (2011) (2)
- Changes in multiparametric prostate MRI and immune subsets in patients (Pts) receiving neoadjuvant immunotherapy and androgen deprivation therapy (ADT) prior to radiation. (2017) (2)
- Abstract CT132: Safety of avelumab (MSB0010718C), an anti-PD-L1 antibody: updated analysis from the phase Ib JAVELIN Solid Tumor trial (2016) (2)
- A trial of CV301 in combination with anti-PD-1 therapy versus anti-PD-1 therapy in subjects with non-small cell lung cancer. (2018) (2)
- A phase I and randomized phase II study of cabozantinib plus docetaxel and prednisone (C+DP) versus docetaxel and prednisone (DP) alone in metastatic castrate-resistant prostate cancer (mCRPC). (2019) (2)
- CRLX101 plus olaparib in patients with metastatic castration-resistant prostate cancer. (2018) (2)
- Safety profile of poxviral vaccines: NCI experience. (2013) (2)
- Radium-223 in prostate cancer: emitting the right signals. (2016) (2)
- Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer (2019) (2)
- Long-Term Survival and PSA Control with Radiation and Immunotherapy for Node Positive Prostate Cancer (2010) (2)
- Calculation of an immunoscore based on extensive flow cytometry analysis of PBMCs from metastatic breast cancer patients treated with docetaxel alone or in combination with vaccine. (2013) (2)
- Non-synergy of PD-1 blockade with T-cell therapy in solid tumors (2022) (2)
- Fast Clearance of the SARS-CoV-2 Virus in a Patient Undergoing Vaccine Immunotherapy for Metastatic Chordoma: A Case Report (2020) (2)
- A phase I, open-label, multiple-ascending-dose trial to investigate the safety, tolerability, pharmacokinetics, biological, and clinical activity of M7824, a novel bifunctional fusion protein targeting the PD-L1 and TGF-β pathways, in patients with metastatic or locally advanced solid tumors (2016) (2)
- Contrasting autoimmune and treatment effects reveals baseline set points of immune toxicity following checkpoint inhibitor treatment (2022) (2)
- A phase I study of the multikinase inhibitor cabozantinib (C) plus docetaxel (D) and prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC). (2014) (2)
- Association of NaF PET/CT findings with PSA and alkaline phosphatase in untreated castration-sensitive prostate cancer. (2015) (2)
- Impact of angiotensin II pathway inhibition on tumor response to anti PD(L)1 based therapy (2020) (2)
- Droplet-Digital PCR Provides a Rapid, Accurate and Cost-Effective Method for Identification of Biomarker FcóRIIIa-F158V Genotypes (2017) (2)
- SO-28 A randomized phase II trial of mFOLFOX6-based standard of care alone or in combination with Ad-CEA vaccine plus avelumab in patients with previously untreated metastatic colorectal cancer (2020) (2)
- Chapter 20 – Recombinant TRICOM-based Therapeutic Cancer Vaccines: Lessons Learned (2013) (2)
- The Bethesda Handbook of Clinical Oncology, 4e (2014) (2)
- Vaccine therapy for a patient with androgen-insensitive prostate cancer without evidence of measurable disease on scans. (2004) (2)
- A pilot trial of a combination of therapeutic vaccines (GI-4000 and GI-6207) as adjunctive therapy with first-line therapy with bevacizumab plus either FOLFOX or FOLFIRI in stage IV patients with newly diagnosed Ras-mutant positive or negative metastatic colorectal cancer. (2012) (2)
- Prospect: A randomized, double-blind, phase III efficacy trial of PROSTVAC. (2012) (2)
- A randomized phase II clinical trial of enzalutamide in combination with the therapeutic cancer vaccine, PSA tricom, in metastatic, castration resistant prostate cancer. (2013) (2)
- Abstract OT1-08-01: A phase Ib trial of sequential combinations of BN-brachyury, entinostat, ado-trastuzumab emtansine (T-DM1) and bintrafusp alfa (M7824) in advanced stage breast cancer (BrEAsT) (2020) (2)
- A phase I study of TRC105 (anti-CD105 monoclonal antibody) in metastatic castration-resistant prostate cancer (mCRPC). (2011) (2)
- The Bethesda handbook of clinical oncology: Fourth edition (2014) (2)
- 681P Clinical and immune responses to immunotherapy in biochemically recurrent (non-metastatic castration sensitive) prostate cancer (BCRpc) (2020) (2)
- Evaluating the optimal sequence of immunotherapy and docetaxel in men with metastatic castration-sensitive prostate cancer. (2022) (2)
- The impact of leukapheresis on immune-cell number and function in patients with advanced cancer (2015) (2)
- Current perspectives in prostate cancer vaccines. (2009) (2)
- Ferumoxytol enhanced MRI for lymph node staging in prostate cancer. (2015) (2)
- 456 Impact of angiotensin II pathway inhibition on tumor response to anti PD(L)1 based therapy (2020) (2)
- Correlates of response to anti-PD-1 immune checkpoint blockade (ICB) in mismatch repair proficient (MMRp) and deficient (MMRd) patients (pts) with metastatic castration resistant prostate cancer (mCRPC). (2018) (2)
- CAR T cells reach clinical milestone in prostate cancer (2022) (2)
- A phase I trial of a recombinant CEA yeast-based vaccine targeting CEA-expressing cancers. (2012) (2)
- Characteristics of patients admitted to the ICU with Kaposi sarcoma herpesvirus-associated diseases (2022) (2)
- Impact of androgen deprivation therapy on the thymus and the production of naïve T-cells (2013) (1)
- Adding fuel to the fire: Immunogenic intensification (2014) (1)
- Use of supportive measures to improve outcome and decrease toxicity in docetaxel-based antiangiogenesis combinations in metastatic castrate resistant prostate cancer (mCRPC). (2013) (1)
- therapeutic vaccines for colorectal cancer (2004) (1)
- PD-1 and PD-L1 expression on PBMC subsets in normal individuals and cancer patients (2014) (1)
- Association of efficacy and adverse events of special interest of avelumab in the JAVELIN solid tumor and JAVELIN Merkel 200 trials. (2018) (1)
- A case report of multiple primary prostate tumors with differential drug sensitivity (2020) (1)
- Digital immunohistochemistry analysis of intratumoral immune infiltrates in prostate cancer patients treated with intraprostatic/systemic PSA-TRICOM vaccine (2013) (1)
- A Phase 2, Double-blind, Randomized Controlled Trial of PROSTVAC in Prostate Cancer Patients on Active Surveillance. (2022) (1)
- 420 PROSTVAC in combination with nivolumab enhanced immune cell infiltration in prostate cancer (2021) (1)
- A pilot study on the clinical value of 18F-sodium fluoride PET/CT in advanced prostate cancer. (2012) (1)
- TRICOM Poxviral-Based Vaccines for the Treatment of Cancer (2014) (1)
- Abstract 1586: Recovery and characterization of circulating tumor cells (CTCs) in cryopreserved metastatic castrate-resistant prostate cancer (mCRPC) patient samples (2015) (1)
- Effect of CD4+ T cell count on treatment-emergent adverse events among patients with and without HIV receiving immunotherapy for advanced cancer (2022) (1)
- Phase II trial of bevacizumab and lenalidomide with docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC). (2012) (1)
- Bintrafusp Alfa: A Bifunctional Fusion Protein Targeting PD-L1 and TGF-β, in Patients with Pretreated Colorectal Cancer: Results from a Phase I Trial (2022) (1)
- Intelligent Sight and Sound: A Chronic Cancer Facial Pain Dataset (2021) (1)
- Abstract 5012: A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: Immune correlates (2014) (1)
- Combination of a therapeutic cancer vaccine and immune checkpoint inhibitors in prostate cancer. (2018) (1)
- Long-term follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck (SCCHN). (2021) (1)
- Anaplastic features (AnaF) and DNA-damage repair pathway (DDR) mutations in metastatic castration-resistant prostate cancer (mCRPC). (2021) (1)
- Artificial intelligence assisted bone lesion detection and classification in computed tomography scans of prostate cancer patients. (2020) (1)
- A sequential cohort study of combination immunotherapy with BN-brachyury vaccine, M7824, ALT-803 and epacadostat in metastatic castration-resistant prostate cancer (mCRPC) (QuEST1). (2018) (1)
- Joint-Predominant Rheumatic Complications of Immune Checkpoint Inhibitor Therapy in Patients with Thymic Epithelial Tumors. (2022) (1)
- A Phase I Single-Arm Study of Biweekly NHS-IL12 in Patients With Metastatic Solid Tumors. (2023) (1)
- Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC) (2022) (1)
- Phase II trial of bevacizumab (A), lenalidomide (R), docetaxel (D), and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). (2011) (1)
- Preclinical and clinical studies of bintrafusp alfa, a novel bifunctional anti-PD-L1/TGFβRII agent: Current status (2022) (1)
- A phase I study of bintrafusp alfa (M7824) and NHS-IL12 (M9241) alone and in combination with stereotactic body radiation therapy (SBRT) in adults with metastatic non-prostate genitourinary malignancies. (2021) (1)
- Preliminary results of a prospective study of 18F-NAF PET/CT in prostate cancer. (2013) (1)
- Resistance to Immunotherapy: Mechanisms and Means for Overcoming. (2021) (1)
- Phase 1 trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in advanced solid tumors (2017) (1)
- Phase I trial of CV301 in combination with anti-PD-1 therapy in non-squamous NSCLC (2019) (1)
- Short course enzalutamide monotherapy in biochemically recurrent prostate cancer: Clinical and immunologic impact. (2016) (1)
- Intelligent Sight and Sound: A Chronic Cancer Pain Dataset (2022) (1)
- Intermittent short course enzalutamide in biochemically recurrent prostate cancer: Analysis of PSA recovery, testosterone levels and tolerability. (2018) (1)
- A phase I study of cabozantinib (Cabo) plus docetaxel (D) and prednisone (P) in metastatic castrate resistant prostate cancer (mCRPC). (2013) (1)
- Use of supportive measures to improve outcome and decrease toxicity in docetaxel-based antiangiogenesis combinations. (2013) (1)
- Randomized phase II clinical trial to assess MUC1 specific immune response to L-BLP25 vaccine in addition to standard therapy in newly diagnosed high-risk prostate cancer. (2012) (1)
- The immunocytokine M9241 in the treatment of prostate cancer (PCa): Clinical and immune data from a phase 1 study. (2022) (1)
- 483 Initial safety results and immune responses induced by a novel human papillomavirus (HPV)-specific gorilla adenovirus immunotherapy vaccine, PRGN-2009, in patients with advanced HPV-associated cancers (2021) (1)
- Re: Interdisciplinary Critique of Sipuleucel-T (2012) (1)
- Prostate cancer: Intermediate efficacy end points to assess modern therapies (2013) (1)
- Pox Viral Vaccines (2004) (1)
- Highlights of the 31st annual meeting of the Society for Immunotherapy of Cancer (SITC), 2016 (2017) (1)
- Imaging metastatic prostate cancer with 18F-DCFBC PET/CT (DCFBC) and 18F-NaF PET/CT (NaF). (2017) (1)
- Long-term avelumab in advanced non-small-cell lung cancer: summaries and post hoc analyses from JAVELIN Solid Tumor (2022) (1)
- Abstract 5520: Therapeutic vaccination with epitope-enhanced and wild-type TARP peptides in stage D0 prostate cancer (2011) (1)
- Multi-spectral immunofluorescence evaluation of the myeloid, T cell, and natural killer cell tumor immune microenvironment in chordoma may guide immunotherapeutic strategies (2022) (1)
- 643P Evaluating biomarkers in metastatic castration resistant prostate cancer (mCRPC) patients (Pts) treated with enzalutamide (Enza): PSA, circulating tumor cell (CTC) counts, AR-V7 status, PET imaging vs. CT & Tc99 scans (2020) (1)
- Case Report: Single-Cell Transcriptomic Analysis of an Anaplastic Oligodendroglioma Post Immunotherapy (2021) (1)
- Impact of standard chemotherapy on peripheral blood immune cell subsets in metastatic colorectal cancer. (2015) (1)
- Phase II evaluation of the combination of PDS0101, M9241, and bintrafusp alfa in patients with HPV 16+ malignancies. (2022) (1)
- A phase I/II study of bintrafusp alfa and NHS-IL12 in combination with docetaxel in adults with metastatic castration sensitive (mCSPC) and castration-resistant prostate cancer (mCRPC). (2021) (1)
- A rare insight into the immunosuppressive landscape of prostate cancer bone metastases. (2021) (1)
- Patients with undetectable PSA 2 years after docetaxel for metastatic castration sensitive prostate cancer (mCSPC). (2021) (1)
- Safety evaluation of M9241 in combination with docetaxel in metastatic prostate cancer. (2022) (1)
- Avelumab in Men With Metastatic Castration-Resistant Prostate Cancer, Enriched for Patients Treated Previously With a Therapeutic Cancer Vaccine (2023) (0)
- A Phase 2 Study of Seviteronel (INO-464) in Patients with Metastatic Castration-Resistant Prostate Cancer Post-Enzalutamide Treatment (2020) (0)
- Personalized peptide vaccine in prostate cancer: capitalizing on existing immunity (2016) (0)
- TWO Therapeutic Cancer Vaccines (2014) (0)
- Abstract LB-A06: Pipeline for High Throughput Analysis of Exosomes in Clinical Biofluids (2018) (0)
- MO01.27 Three-Year Follow-up of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, as Second-Line (2L) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) (2021) (0)
- Abstract CT080: Pharmacokinetic and pharmacodynamic analysis of M7824, a dual anti-PD-L1 and TGFβ TRAP molecule, in the first-in-human phase I dose escalation study (2017) (0)
- Abstract B51: Circulating regulatory T-cell function and overall survival in metastatic castration-resistant prostate cancer (mCRPC) patients treated with vaccine. (2011) (0)
- Abstract 3516: A genomics model to predict immune-related adverse events in cancer patients treated with checkpoint inhibitors (2019) (0)
- Molecular Pathways and Mechanisms of TGFβ in Cancer Therapy. (2023) (0)
- Tumor cell HLA class I expression and pathologic response following neoadjuvant immunotherapy for newly diagnosed head and neck cancer. (2023) (0)
- Cancer Patient Tobacco Use Questionnaire (2018) (0)
- Immune correlates with response in patients with metastatic solid tumors treated with a tumor targeting immunocytokine NHS-IL12 (2023) (0)
- Standardizing measurement of tobacco use in cancer clinical trials. (2014) (0)
- New frontiers in therapy for metastatic prostate cancer (2010) (0)
- Interleukin-15 (IL-5) in Combination with Avelumab in Relapsed/Refractory Mature T-Cell Malignancies (2019) (0)
- Highlights on FOXO3 and tumor-associated dendritic cells in prostate cancer. (2011) (0)
- Immunity Contribute to T Cell Activation and Tumor Soluble CD 27-Pool in Humans (2013) (0)
- Phase 1b results of avelumab in patients (pts) with previously treated metastatic melanoma enrolled in the JAVELIN Solid Tumor trial, including updated subgroup analyses. (2018) (0)
- Abstract LB-059: Neoadjuvant immunotherapy with androgen deprivation therapy (ADT) prior to radiation in prostate cancer: Impact on multiparametric prostate MRI and immune responses (2017) (0)
- A study of intense neoadjuvant testosterone lowering therapy with goserelin and enzalutamide (Enza) in high-risk prostate cancer (PC) with multiparametric MRI (mpMRI). (2019) (0)
- Abstract 1406: Analysis of immune responses as a consequence of androgen deprivation therapy in patients with biochemical progression of prostate cancer (2016) (0)
- Analysis of PSA-Specific T-Cell Responses of Prostate Cancer Patients Given a PSA-Based Vaccine on a Clinical Trial (2003) (0)
- Acknowledgment of Reviewers 2021. (2021) (0)
- Novel immunotherapeutic agents for castration-resistant prostate cancer: update from clinical trials (2013) (0)
- 438 Interrogation of immune toxicity in patients with thymic epithelial tumors (TETs) (2022) (0)
- The effect of deep AR suppression with enzalutamide or apalutamide on endogenous glucocorticoids: Implications for adverse effects and development of combination therapies. (2020) (0)
- Circulating Tumor Cell Subtypes and T-cell Populations as Prognostic Biomarkers to Combination Immunotherapy in Patients with Metastatic Genitourinary Cancer A C (2021) (0)
- Vaccine Therapy and Integration with Other Modalities (2013) (0)
- Androgens, androgen suppression, and prostate cancer: Recent preclinical and clinical findings and implications (2012) (0)
- PSMA PET findings in patients with undetectable PSA more than 3 years after docetaxel for metastatic castration-sensitive prostate cancer (mCSPC). (2022) (0)
- A Single-arm Phase II Study Combining NLG207, a Nanoparticle Camptothecin, with Enzalutamide in Advanced Metastatic Castration-resistant Prostate Cancer Post-Enzalutamide. (2022) (0)
- Immune impact induced by PSA-tricom, a therapeutic vaccine for prostate cancer. (2014) (0)
- Abstract A42: Phase I trial of EUS-guided intratumoral vaccination with recombinant Panvac-F and systemic Panvac-V in patients with locally advanced pancreatic cancer. (2012) (0)
- The Clinical Utility of Bevacizumab (2008) (0)
- Failure in Patients with Advanced Malignancy A Pilot Study of CTLA-4 Blockade after Cancer Vaccine (2007) (0)
- Predicting Outcomes of Indeterminate Bone Lesions on 18F-DCFPyL PSMA PET/CT Scans in the Setting of High-Risk Primary or Recurrent Prostate Cancer (2022) (0)
- Abstract 5524: Generation of cellular immune responses to MUC1-C to target the portion of MUC1 that is most biologically relevant to the transformation process (2011) (0)
- Combining radiation and therapeutic cancer vaccines: a synergistic approach (2012) (0)
- Abstract SY24-02: Development of recombinant vaccines for the prevention and therapy of human carcinomas (2011) (0)
- Evaluation of immune cell subsets of cancer patients treated with Avelumab, a fully human IgG1 anti-PD-L1 MAb capable of mediating ADCC of human tumor cells (2015) (0)
- Development of an Exosome Analysis Pipeline for Precision Oncology (2018) (0)
- Feasibility of continuing docetaxel-based therapy in patients with metastatic castrate-resistant prostate cancer (mCRPC) that experience hypersensitivity reactions (HSR). (2013) (0)
- 978: A Phase II Trial of Docetaxel, Thalidomide and Estramustine in Metastatic Androgen-Independent Prostate Cancer (2006) (0)
- MPA PASS Enables Stitched Multiplex Multi-Dimensional EV Repertoire Analysis (2021) (0)
- Abstract IA07: The QuEST for an effective immunotherapy for prostate cancer (2021) (0)
- Phenotypic plasticity and reduced tissue retention of exhausted tumor-infiltrating T cells following neoadjuvant immunotherapy in head and neck cancer. (2023) (0)
- OP-JNCI200221 799..799 (2021) (0)
- 296 Immune correlates of clinical response to Avelumab in patients with advanced thymic epithelial tumors (2020) (0)
- 375 Expansion of HPV-16 specific T cells in patients with HPV-related cancers treated with bintrafusp alfa (2020) (0)
- Therapeutic Cancer Vaccines: An Emerging Approach to Cancer Treatment (2014) (0)
- Abstract 5379: Combination treatment with Bevacizumab, Lenalidomide, Docetaxel and Prednisone (ART-P) does not impact the immune response in patients with metastatic castration-resistant prostate cancer (2012) (0)
- Abstract 2048: Pharmacodynamic biomarker studies of TRC105 anti-endoglin (CD105) antibody revealed anti-angiogenic activity associated with CD105 depletion (2016) (0)
- Docetaxel Alone or in CombinationWith a Therapeutic Cancer Vaccine ( PANVAC ) in PatientsWithMetastatic Breast Cancer A Randomized Clinical Trial (2015) (0)
- Abstract 3671: Phenotypic heterogeneity within prostate cancer bone metastases measured by18F-DCFBC PET/CT and18F-NaF PET/CT (2018) (0)
- Prostvac-VF:avector-basedvaccine targetingPSAinprostatecancer (2009) (0)
- Abstract B43: Identification of prognostic markers for prostate cancer by serum profiling with a carbohydrate antigen microarray (2010) (0)
- Abstract 736: Development of a novel circulating tumor cell technology for cancer predictive biomarker analysis. (2013) (0)
- 1272P Three-year follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, for second-line (2L) treatment of non-small cell lung cancer (NSCLC) (2020) (0)
- Flow-cytometry phenotypic assessment of immune cell subsets reflecting function for the identification of breast cancer patients receiving vaccine plus docetaxel with longer progression-free survival (2013) (0)
- Recombinant TRICOM-based Therapeutic Cancer Vaccines (2013) (0)
- Phase 1 Study of Safety and Preliminary Clinical Activity of JNJ-63898081, a PSMA and CD3 Bispecific Antibody, for Metastatic Castration-Resistant Prostate Cancer. (2023) (0)
- Abstract 758: Cancer vaccine immunotherapy employing Saccharomyces cerevisiae (yeast) as a vector can modulate the balance between CD4+ T cells and regulatory T cells (Tregs) and enhance the specific antitumor immune response (2011) (0)
- A phase I study of gemcitabine, carboplatin, and lenalidomide for treatment of patients with advanced/metastatic urothelial carcinoma (UC) and other solid tumors. (2014) (0)
- Phase I trial of a modified vaccinia ankara (MVA) priming vaccine followed by a fowlpox virus (FPV) boosting vaccine modified to express brachyury and costimulatory molecules in advanced solid tumors. (2019) (0)
- Spatial colocalization of 18F-DCFPyL PET/CT and 18F-NaF PET/CT within prostate cancer bone metastases (2018) (0)
- Clinical efficacy of abiraterone and enzalutamide metastatic castration sensitive prostate cancer patients who progressed rapidly on docetaxel with a genomic analysis. (2019) (0)
- Abstract 4815: A novel AR splice variant identified in circulating tumor cells from castration-resistant prostate cancer patient blood as a potentially prognostic biomarker (2014) (0)
- Identification and characterization of agonist epitopes of the MUC1-C oncoprotein (2013) (0)
- Abstract 4571: Autologous TARP peptide vaccination is associated with slowing in PSA velocity and a decrease in tumor growth rate in patients with Stage D0 prostate cancer. (2013) (0)
- Degarelix: medical castration without fare (2009) (0)
- Evaluating biomarkers in metastatic castration-resistant prostate cancer patients treated with enzalutamide: PSA, circulating tumor cell counts, AR-V7 status and radiographic progression. (2020) (0)
- Abstract 1230: Impact of apheresis (Aph) on number and function of lymphocytes in cancer patients (pts). (2013) (0)
- 6 Immune correlates of clinical benefit in patients with HPV-associated malignancies treated with bintrafusp alfa (2021) (0)
- Avelumab treatment in metastatic urothelial carcinoma: Association between early response and durable outcomes in the phase Ib JAVELIN Solid Tumor Study. (2019) (0)
- Overcoming resistance mechanisms in a study of cabozantinib (C) plus docetaxel (D) and prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC). (2015) (0)
- Effect of age and cancer on peripheral immune cell subsets and their PD-1 and PD-L1 expression (2015) (0)
- A polymorphism in a transporter of testosterone as a determinant of androgen independence in prostate cancer (2008) (0)
- MP67-16 SURGICAL OUTCOMES IN PATIENTS RECEIVING NEOADJUVANT VACCINE THERAPY (PROSTVAC) PRIOR TO RADICAL PROSTATECTOMY: A PHASE II EXPERIENCE (2023) (0)
- Abstract 2544: Identification of immune signatures predicting for clinical outcome measured by flow-cytometry and immunogenetic analysis of PBMCs from breast cancer patients treated with docetaxel alone or docetaxel plus vaccine (2014) (0)
- If we build it they will come: targeting the immune response to breast cancer (2019) (0)
- Abstract 1316: Evaluation of immune cell subsets of cancer patients treated with a fully human IgG1 anti-PD-L1 MAb (MSB0010718C) capable of mediating ADCC of human tumor cells (2015) (0)
- A phase 1 open label trial of intravenous administration of MVA-BN-Brachyury vaccine in patients with advanced cancer. (2021) (0)
- TO: MEMBERS OF THE CONTRACTORS PRE-QUALIFICATION BOARD (2010) (0)
- Myeloid-Derived Suppressor Cells and Function of Human Monocytic Effect of TLR Agonists on the Differentiation (2015) (0)
- 176 Vector-based Vaccines for Cancer Therapy (2009) (0)
- Abstract CT222: Ferumoxytol enhanced MRI for lymph node staging in genitourinary cancers (2015) (0)
- Flutamide With or Without PROSTVAC in Non-metastatic Castration Resistant (M0) Prostate Cancer. (2023) (0)
- Real-world insights on preferred treatments for steroid-refractory immune checkpoint inhibitor-induced pneumonitis (2021) (0)
- Immunotherapy for prostate cancer (2011) (0)
- Long-term avelumab treatment in patients with advanced non-small cell lung cancer (NSCLC): Post hoc analyses from JAVELIN solid tumour (2019) (0)
- Abstract PL03-02: Current status of recombinant pox-viral vaccines (2012) (0)
- Cancer Immunology, Immunotherapeutics, and Vaccine Approaches (2010) (0)
- Abstract 2546: Analysis of immune cell subsets in a multidrug therapeutic regimen for patients with metastatic castration-resistant prostate cancer (2014) (0)
- The impact of age on sipuleucel-T-induced immune responses. (2015) (0)
- Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients with Non-Small Cell Lung Cancer Resistant or Refractory to Immune Checkpoint Inhibitors (2022) (0)
- Abstract 366: A novel transcript variant of androgen receptor identified in circulating tumor cells from castration-resistant prostate cancer patients as a potentially prognostic biomarker (2015) (0)
- 695 Immune correlates associated with clinical benefit in patients with immune checkpoint refractory HPV-associated malignancies treated with triple combination immunotherapy (2022) (0)
- Novel vaccines for the treatment of gastrointestinal cancers: Commentary (2005) (0)
- Comparison of survival of African-American (AA) patients (pts) in docetaxel (D)-based combination therapies in metastatic castrate-resistant prostate cancer (mCRPC). (2016) (0)
- Immunotherapy to prevent progression on active surveillance study (IPASS): A phase II, randomized, double-blind, controlled trial of PROSTVAC in prostate cancer patients who are candidates for active surveillance. (2022) (0)
- Avelumab treatment in metastatic urothelial carcinoma: Post-hoc analysis of high-risk populations in the phase Ib JAVELIN Solid Tumor Study. (2019) (0)
- Bicalutamide with or without metformin for biochemical recurrence in prostate cancer patients (BIMET-1). (2020) (0)
- World Vaccine Trials Congress 2012 (2012) (0)
- Diffuse lichen planus-like keratoses and clinical pseudo-progression associated with avelumab treatment for Merkel cell carcinoma, a case report (2019) (0)
- CD4+ T-cell count eligibility by HIV status among participants receiving immunotherapy for cancer diagnoses. (2021) (0)
- Antiandrogen (AA), vaccine (V), and combination therapy in D0.5 prostate cancer (CaP) patients (Pts) (2005) (0)
- Phase 1 trial of CV301 in combination with anti‐PD‐1 therapy in nonsquamous non‐small cell lung cancer (2022) (0)
- A Randomized Phase II Study of Concurrent Docetaxel Plus Vaccine Versus VaccineAlone in Metastatic Androgen-Independent Prostate Cancer (2006) (0)
- Phase I neoadjuvant study of intravesical recombinant fowlpox-GM-CSF (rF-GM-CSF) or fowlpox-TRICOM (rF-TRICOM) in patients with bladder carcinoma (2019) (0)
- Abstract 5404: Up-regulation of proliferative and migratory genes in regulatory T cells from patients with metastatic castration-resistant prostate cancer (2012) (0)
- Abstract 498: A combination trial of vaccine plus ipilimumab in patients with metastatic castration-resistant prostate cancer: immune correlates. (2013) (0)
- Q 1 2 Immune Q 2 Impact Induced by PROSTVAC ( PSA-TRICOM ) , Q 3 3 a Therapeutic Vaccine for Prostate Cancer 4 5 (2013) (0)
- Long Term Clinical Outcomes, Toxicity, and Immunologic Response of Patients Treated on a Phase II Trial with Definitive Radiation in Combination with a Viral Vaccine to Prostate-specific Antigen (2010) (0)
- Investigation of antibody dependent cellular cytotoxicity as a mechanism of action for a novel anti-PD-L1 monoclonal antibody (2014) (0)
- Commentary (Schlom et al): Novel Vaccines for the Treatment of Gastrointestinal Cancers (2005) (0)
- Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with targeted therapies (2023) (0)
- Validation of a software-based clinical trial matching platform for oncology using comprehensive clinical information. (2018) (0)
- 582 Immune correlates from QuEST1 in men with castration-resistant prostate cancer (2021) (0)
- In Reply (2020) (0)
- The soluble guanylyl cyclase pathway is inhibited to evade androgen deprivation-induced senescence and enable progression to castration resistance (2023) (0)
- A phase I study of Ad5 PSA/MUC-1/brachyury vaccine in patients with metastatic castration resistant prostate cancer (mCRPC) (2019) (0)
- Evaluation of a new circulating tumor cell (CTC) platform to predict response and survival in metastatic urothelial carcinoma (UC) patients receiving cabozantinib (cabo). (2015) (0)
- Abstract B100: Panvac-F and Panvac-V: Phase I study of intratumoral and systemic vaccination (2015) (0)
- Abstract 2405: Treatment of human dendritic cells with Saccharomyces cerevisiae (yeast) reduces number and function of regulatory T cells (Tregs) and enhances the ratio of antigen-specific effectors to Tregs (2010) (0)
- In Silico Re-Optimization of Atezolizumab Dosing using Population Pharmacokinetic and Exposure-Response Simulation. (2023) (0)
- Predicting clinical outcomes in chordoma patients receiving immunotherapy: a comparison between volumetric segmentation and RECIST (2016) (0)
- 540 Baseline mTOR transcriptional signatures in CD8 T cells are associated with immune-related adverse events but not anti-tumor responses in patients receiving immune checkpoint inhibitors (2021) (0)
- Combining Vaccines with Therapies that Render Tumor Cells more Susceptible to Immune Mediated Killing (2013) (0)
- 970 PROSPECT: A RANDOMIZED, DOUBLE-BLIND, PHASE 3 EFFICACY TRIAL OF PROSTVAC-VF IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (2013) (0)
- Phase II evaluation of combination immunotherapy with CV301, N-803, bintrafusp alfa, and M9241 in patients with advanced small bowel and colorectal cancers. (2023) (0)
- An analysis of sodium 18f-fluoride PET/CT and prostate specific antigen (PSA) changes in men with metastatic castration resistant prostate cancer (mCRPC). (2016) (0)
- Combining a Recombinant CancerVaccinewith Standard Definitive Radiotherapy in Patientswith Localized Prostate Cancer (2005) (0)
- Docetaxel-based therapy for prostate cancer (2005) (0)
- Abstract CN04-01: Targeting the epithelial-mesenchymal transition via brachyury-based cancer vaccines (2015) (0)
- Anaplastic Features in Advanced Prostate Cancer With and Without DNA Damage Repair Mutations. (2021) (0)
- 605P Analysis of serial PET imaging and paired Tc99 scans in metastatic castration resistant prostate cancer (mCRPC) treated with enzalutamide (2021) (0)
- HLA-A*03 is a Predictive Biomarker of Poor Response to Immune Checkpoint Blockade in Cancer (2021) (0)
- A phase I study of TRC105 (anti-CD105 [endoglin] antibody) in metastatic castration-resistant prostate cancer (mCRPC). (2012) (0)
- Nuts and Bolts of Cancer Immunotherapy (2014) (0)
- Molecules in Human Dendritic Cells Vector-mediated Hyperexpression of a Triad of Costimulatory Enhanced Activation of Human T Cells via Avipox Updated (2001) (0)
- Abstract IA24: Making immunotherapy work in prostate cancer (2018) (0)
- 766 Phase I/II evaluation of the combination of entinostat, M9241 and bintrafusp alfa in patients with advanced HPV related malignancies (2022) (0)
- Comprar The Bethesda Handbook of Clinical Oncology, 4e | Jame Abraham MD, FACP | 9781451187588 | Lippincott Williams & Wilkins (2014) (0)
- ARandomized Phase II Study of Concurrent Docetaxel Plus Vaccine Versus VaccineAlone inMetastatic Androgen-Independent Prostate Cancer (2006) (0)
- Combination Immunotherapy Lymphocytes: A Rationale for Its Use in Lymphocytes while Preserving Effector T Decreases Human T Regulatory Pan-Bcl-2 Inhibitor, GX15-070 (Obatoclax), (2014) (0)
- Reply to L. León et al (2010) (0)
- Prediction of cancer treatment response from histopathology images through imputed transcriptomics (2022) (0)
- 265 Phase 1b study of avelumab + M9241 (NHS-IL12) in patients with advanced solid tumors: interim analysis results from a urothelial carcinoma (UC) dose-expansion cohort (2020) (0)
- Abstract C241: Phase I trial of EUS-guided intratumoral vaccination with recombinant Panvac-F and systemic Panvac-V in patients with locally advanced pancreatic cancer. (2011) (0)
- Deep AR suppression in prostate cancer exploits sexually dimorphic renal expression for systemic glucocorticoid exposure (2020) (0)
- Assessment of Aortoiliac Atherosclerotic Plaque on CT in Prostate Cancer Patients Undergoing Treatment (2022) (0)
- Pembrolizumab: patient selection or immune intensification? (2018) (0)
- Phase I Trial of a PSA based vaccine and ipilimumab in patients (pts) with metastatic castrate resistant prostate cancer (CRPC) (2007) (0)
- 1337 Preclinical evaluation of STAR0602, a novel, first-in-class anti-TCR Vb targeted bispecific antibody with potent anti-tumor activity for PD-1 refractory solid tumors (2022) (0)
- A randomized, phase II trial of ketoconazole plus alendronate versus ketoconazole alone in patients with androgen independent (2005) (0)
- Celebrating a decade of the Journal for ImmunoTherapy of Cancer (2022) (0)
- 14937 Keratoacanthomas associated with anti–TGF-β immunotherapy (2020) (0)
- Effects of docetaxel on circulating immune cell subsets and association with outcomes in metastatic castration-sensitive prostate cancer. (2023) (0)
- Analysis of demographic characteristics and disparities of enrollment in cancer clinical research at the U.S. National Cancer Institute (NCI): A 15-year experience. (2022) (0)
- Abstract CN07-03: Brachyury and the interleukin-8 axis in tumor progression (2018) (0)
- Metformin for biochemical recurrence of prostate cancer: Immune data from a phase 2 study. (2023) (0)
- ARv567es as detected in circulating tumor cells: An innovative methodology for the detection of a prognostic and therapeutic biomarker. (2014) (0)
- Abstract CT058: A phase 2 open-label study to evaluate the efficacy and safety of VT-464 in patients with androgen receptor positive triple-negative breast cancer patients, and men with ER positive breast cancer (2017) (0)
- Even more cost savings? (2006) (0)
- Adaptive Immunity in Genitourinary Cancers. (2023) (0)
- Impact of age on antigen-specific T lymphocyte response in patients treated with PSA-TRICOM (2014) (0)
- Abstract 5378: Phase I trial of EUS-guided intratumoral vaccination with recombinant Panvac-F and systemic Panvac-V in patients with locally advanced pancreatic cancer (2012) (0)
- Erratum: Hormonal therapy for prostate cancer (The Journal of Urology 173, 5 (1567)) (2005) (0)
- Issues in Pre-clinical Models, Clinical Trial Design and Analytical Considerations in Developing and Evaluating Novel Cancer Immunotherapies (2013) (0)
- A tale of lineage plasticity: Intense neoadjuvant testosterone lowering therapy in localized prostate cancer (PCa) harboring high-risk genomic signatures. (2020) (0)
- Response to: Primary Adrenal Insufficiency due to Immune Checkpoint Inhibitors; more common than we thought. (2020) (0)
- Spatial analysis of tumor immune microenvironment (TIME) in patients treated with Bintrafusp alfa. (2020) (0)
- Phase I expansion cohort trial to investigate the safety and clinical activity of avelumab (MSB0010718C) in patients with metastatic or locally advanced solid tumors. (2015) (0)
- SUN-739 Next Generation AR Antagonists Increase Systemic Active Glucocorticoid Exposure by Altering Glucocorticoid Metabolism (2020) (0)
This paper list is powered by the following services:
Other Resources About James L. Gulley
What Schools Are Affiliated With James L. Gulley?
James L. Gulley is affiliated with the following schools:
